With regard to TZD (PPARγ agonists), their use for treating NAFLD has been reported to improve steatosis, inflammation, fibrosis, and insulin resistance, and the AASLD and EASL guidelines recommend their use in patients with NASH [36]. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatohepatitis.